Seattle Genetics rated at perform by RBC

RBC Capital Markets analyst Jason Kantor rated Seattle Genetics, Inc. at sector perform and above average risk on news that results for SGN-40 in non-Hodgkin's lymphoma are among the best results seen at ASCO, according to the analyst. Five of 29 patients had objective responses including one complete response. Shares of the Bothell, Wash.-based biotechnology company were down $0.26, or 5.98%, at $4.09 on volume of 220,115 shares versus the three-month running average of 212,835shares. (Nasdaq: SGEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.